AWG
MLTX icon

Alpha Wave Global’s MoonLake Immunotherapeutics MLTX Stock Holding History

Alpha Wave Global’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-448,882
Closed -$4.49M – 133
2022
Q1 		$4.49M Buy
448,882
+141,047
+46% +$1.4M 0.4% 75
2021
Q4 		$3.04M Buy
+307,835
New +$3.06M 0.34% 65

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Alpha Wave Global's MLTX Position: Q2 2022 in Review

Alpha Wave Global sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2022, closing a stake of 448,882 shares — an estimated $4.49M sold.

Alpha Wave Global first reported a position in MLTX in Q4 2021 and held it in 2 quarters. The position peaked at $4.49M in Q1 2022. 23 funds tracked by Wall St. Rank hold MLTX as of Q2 2022.

  • Alpha Wave Global reported no remaining MoonLake Immunotherapeutics position as of Q2 2022 after selling out during the quarter.
  • Alpha Wave Global sold 448,882 MoonLake Immunotherapeutics shares in Q2 2022, an estimated $4.49M.
  • Alpha Wave Global first reported a position in MoonLake Immunotherapeutics in Q4 2021 and held it in 2 quarters.
  • Alpha Wave Global's MoonLake Immunotherapeutics position peaked at $4.49M in Q1 2022.
  • 23 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2022.

Based on Alpha Wave Global's 13F filing for Q2 2022, filed 12 Aug 2022.